SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-17-003061
Filing Date
2017-04-28
Accepted
2017-04-28 16:48:52
Documents
5
Period of Report
2017-06-21
Effectiveness Date
2017-04-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2231999zdef14a.htm DEF 14A 666187
2 G111872BGI001.GIF g111872bgi001.gif GRAPHIC 190270
3 G111872BGI002.GIF g111872bgi002.gif GRAPHIC 175151
4 G1039423.JPG g1039423.jpg GRAPHIC 16435
5 G755814.JPG g755814.jpg GRAPHIC 88420
  Complete submission text file 0001047469-17-003061.txt   1315426
Mailing Address 101 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RY
Business Address 101 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RY 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 001-37368 | Film No.: 17796474
SIC: 2836 Biological Products, (No Diagnostic Substances)